Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Stimcell Energetics ( (STME) ) has issued an update.
On December 2, 2025, StimCell Energetics Inc. announced a service agreement with the St. Boniface Hospital Albrechtsen Research Centre to study the effects of its eBalance® device on mitochondrial function in cultured sensory neurons. This collaboration, led by Dr. Paul Fernyhough, aims to explore the physiological action of microcurrents and assess the device’s impact on cellular energy production. The study will involve a series of experiments to measure various aspects of mitochondrial function, with results potentially opening new therapeutic avenues in neurology. This partnership underscores StimCell’s commitment to advancing cellular energy solutions and evidence-based innovation.
More about Stimcell Energetics
StimCell Energetics Inc. is a biotech company focused on the discovery, development, and commercialization of products that enhance cellular function and promote wellness. The company targets areas such as aging, insulin sensitivity, high blood pressure, neuropathy, and kidney function, with a primary focus on its eBalance® Technology and eBalance® Home System.
Average Trading Volume: 1,734
Technical Sentiment Signal: Hold
Current Market Cap: $7.33M
Learn more about STME stock on TipRanks’ Stock Analysis page.